From Benzinga’s Global Small Cap Conference: Journey Medical President & CEO, Claude Maraoui & CFO Ernest De Paolantonio Begins Presenting
https://www.youtube.com/watch?v=XkOilNZqoEI
B. Riley Securities Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $14
B. Riley Securities initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $14.
